Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10909236 | Leukemia Research | 2012 | 5 Pages |
Abstract
Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30 mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (n = 4) and ototoxicity (n = 4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Virginia M. Klimek, Emily K. Dolezal, Larry Smith, Gerald Soff, Stephen D. Nimer,